# Universal Display Corp \\pa\\: financial statements, quarterly

OLED · Nasdaq · CIK 1005284 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/oled.md) · [Financials](/companies/oled/financials.md) · [Filings](/companies/oled/filings.md) · [Insiders](/companies/oled/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/oled/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [141](/filings/0000950170-24-118989.md) | [158 d](/filings/0001193125-26-059371.md) | [165](/filings/0000950170-25-061835.md) | [159](/filings/0000950170-25-100901.md) | [162](/filings/0001193125-25-269542.md) | [162 d](/filings/0001193125-26-059371.md) | [166](/filings/0001193125-26-197277.md) | [172](/filings/0001193125-26-326123.md) | [140](/filings/0001193125-25-269542.md) | [173 d](/filings/0001193125-26-059371.md) | [142](/filings/0001193125-26-197277.md) | [152](/filings/0001193125-26-326123.md) |
| Cost of revenue | $m | [34.2](/filings/0000950170-24-118989.md) | [36.0 d](/filings/0001193125-26-059371.md) | [37.0](/filings/0000950170-25-061835.md) | [38.3](/filings/0000950170-25-100901.md) | [35.8](/filings/0001193125-25-269542.md) | [37.4 d](/filings/0001193125-26-059371.md) | [38.1](/filings/0001193125-26-197277.md) | [39.2](/filings/0001193125-26-326123.md) | [35.5](/filings/0001193125-25-269542.md) | [41.3 d](/filings/0001193125-26-059371.md) | [36.1](/filings/0001193125-26-197277.md) | [36.8](/filings/0001193125-26-326123.md) |
| Gross profit | $m | [107](/filings/0000950170-24-118989.md) | [122 d](/filings/0001193125-26-059371.md) | [128](/filings/0000950170-25-061835.md) | [120](/filings/0000950170-25-100901.md) | [126](/filings/0001193125-25-269542.md) | [125 d](/filings/0001193125-26-059371.md) | [128](/filings/0001193125-26-197277.md) | [133](/filings/0001193125-26-326123.md) | [104](/filings/0001193125-25-269542.md) | [132 d](/filings/0001193125-26-059371.md) | [106](/filings/0001193125-26-197277.md) | [115](/filings/0001193125-26-326123.md) |
| Research and development | $m | [33.1](/filings/0000950170-24-118989.md) | [33.6 d](/filings/0001193125-26-059371.md) | [38.0](/filings/0000950170-25-061835.md) | [36.8](/filings/0000950170-25-100901.md) | [36.1](/filings/0001193125-25-269542.md) | [46.3 d](/filings/0001193125-26-059371.md) | [34.9](/filings/0001193125-26-197277.md) | [36.4](/filings/0001193125-26-326123.md) | [36.3](/filings/0001193125-25-269542.md) | [38.5 d](/filings/0001193125-26-059371.md) | [35.2](/filings/0001193125-26-197277.md) | [35.0](/filings/0001193125-26-326123.md) |
| Selling, general and administrative | $m | [18.1](/filings/0000950170-24-118989.md) | [16.8 d](/filings/0001193125-26-059371.md) | [19.3](/filings/0000950170-25-061835.md) | [19.8](/filings/0000950170-25-100901.md) | [15.7](/filings/0001193125-25-269542.md) | [19.5 d](/filings/0001193125-26-059371.md) | [17.0](/filings/0001193125-26-197277.md) | [20.4](/filings/0001193125-26-326123.md) | [18.0](/filings/0001193125-25-269542.md) | [18.8 d](/filings/0001193125-26-059371.md) | [20.0](/filings/0001193125-26-197277.md) | [18.6](/filings/0001193125-26-326123.md) |
| Operating income | $m | [48.4](/filings/0000950170-24-118989.md) | [64.7 d](/filings/0001193125-26-059371.md) | [62.9](/filings/0000950170-25-061835.md) | [56.4](/filings/0000950170-25-100901.md) | [67.0](/filings/0001193125-25-269542.md) | [52.5 d](/filings/0001193125-26-059371.md) | [69.7](/filings/0001193125-26-197277.md) | [68.5](/filings/0001193125-26-326123.md) | [43.1](/filings/0001193125-25-269542.md) | [67.2 d](/filings/0001193125-26-059371.md) | [42.8](/filings/0001193125-26-197277.md) | [53.6](/filings/0001193125-26-326123.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [2.4](/filings/0000950170-24-118989.md) | [13.6 d](/filings/0001193125-26-059371.md) | [13.6](/filings/0000950170-25-061835.md) | [12.6](/filings/0000950170-25-100901.md) | [14.5](/filings/0001193125-25-269542.md) | [9.3 d](/filings/0001193125-26-059371.md) | [15.7](/filings/0001193125-26-197277.md) | [16.6](/filings/0001193125-26-326123.md) | [10.1](/filings/0001193125-25-269542.md) | [10.3 d](/filings/0001193125-26-059371.md) | [9.4](/filings/0001193125-26-197277.md) | [11.6](/filings/0001193125-26-326123.md) |
| Net income | $m | [51.5](/filings/0000950170-24-118989.md) | [62.0 d](/filings/0001193125-26-059371.md) | [56.9](/filings/0000950170-25-061835.md) | [52.3](/filings/0000950170-25-100901.md) | [66.9](/filings/0001193125-25-269542.md) | [46.0 d](/filings/0001193125-26-059371.md) | [64.4](/filings/0001193125-26-197277.md) | [67.3](/filings/0001193125-26-326123.md) | [44.0](/filings/0001193125-25-269542.md) | [66.3 d](/filings/0001193125-26-059371.md) | [35.9](/filings/0001193125-26-197277.md) | [49.4](/filings/0001193125-26-326123.md) |
| Diluted EPS | $ per share | [1.08](/filings/0000950170-24-118989.md) | not reported | [1.19](/filings/0000950170-25-061835.md) | [1.10](/filings/0000950170-25-100901.md) | [1.40](/filings/0001193125-25-269542.md) | not reported | [1.35](/filings/0001193125-26-197277.md) | [1.41](/filings/0001193125-26-326123.md) | [0.92](/filings/0001193125-25-269542.md) | not reported | [0.76](/filings/0001193125-26-197277.md) | [1.06](/filings/0001193125-26-326123.md) |
| Basic EPS | $ per share | [1.08](/filings/0000950170-24-118989.md) | not reported | [1.19](/filings/0000950170-25-061835.md) | [1.10](/filings/0000950170-25-100901.md) | [1.40](/filings/0001193125-25-269542.md) | not reported | [1.35](/filings/0001193125-26-197277.md) | [1.41](/filings/0001193125-26-326123.md) | [0.93](/filings/0001193125-25-269542.md) | not reported | [0.76](/filings/0001193125-26-197277.md) | [1.06](/filings/0001193125-26-326123.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [79.3](/filings/0000950170-23-058202.md) | [92.0](/filings/0000950170-25-024151.md) | [74.0](/filings/0000950170-24-052114.md) | [92.9](/filings/0000950170-24-089283.md) | [79.6](/filings/0000950170-24-118989.md) | [99.0](/filings/0001193125-26-059371.md) | [157](/filings/0000950170-25-061835.md) | [95.8](/filings/0000950170-25-100901.md) | [122](/filings/0001193125-25-269542.md) | [138](/filings/0001193125-26-326123.md) | [159](/filings/0001193125-26-197277.md) | [121](/filings/0001193125-26-326123.md) |
| Current assets | $m | [879](/filings/0000950170-23-058202.md) | [917](/filings/0000950170-25-024151.md) | [921](/filings/0000950170-24-052114.md) | [959](/filings/0000950170-24-089283.md) | [942](/filings/0000950170-24-118989.md) | [900](/filings/0001193125-26-059371.md) | [1,018](/filings/0000950170-25-061835.md) | [1,011](/filings/0000950170-25-100901.md) | [1,037](/filings/0001193125-25-269542.md) | [1,087](/filings/0001193125-26-326123.md) | [932](/filings/0001193125-26-197277.md) | [942](/filings/0001193125-26-326123.md) |
| Total assets | $m | [1,623](/filings/0000950170-23-058202.md) | [1,669](/filings/0000950170-25-024151.md) | [1,684](/filings/0000950170-24-052114.md) | [1,777](/filings/0000950170-24-089283.md) | [1,811](/filings/0000950170-24-118989.md) | [1,832](/filings/0001193125-26-059371.md) | [1,864](/filings/0000950170-25-061835.md) | [1,932](/filings/0000950170-25-100901.md) | [1,947](/filings/0001193125-25-269542.md) | [1,964](/filings/0001193125-26-326123.md) | [1,895](/filings/0001193125-26-197277.md) | [1,888](/filings/0001193125-26-326123.md) |
| Current liabilities | $m | [131](/filings/0000950170-23-058202.md) | [119](/filings/0000950170-25-024151.md) | [95.0](/filings/0000950170-24-052114.md) | [152](/filings/0000950170-24-089283.md) | [131](/filings/0000950170-24-118989.md) | [125](/filings/0001193125-26-059371.md) | [113](/filings/0000950170-25-061835.md) | [126](/filings/0000950170-25-100901.md) | [109](/filings/0001193125-25-269542.md) | [108](/filings/0001193125-26-326123.md) | [97.8](/filings/0001193125-26-197277.md) | [111](/filings/0001193125-26-326123.md) |
| Total liabilities | $m | [241](/filings/0000950170-23-058202.md) | [222](/filings/0000950170-25-024151.md) | [199](/filings/0000950170-24-052114.md) | [250](/filings/0000950170-24-089283.md) | [224](/filings/0000950170-24-118989.md) | [216](/filings/0001193125-26-059371.md) | [205](/filings/0000950170-25-061835.md) | [217](/filings/0000950170-25-100901.md) | [203](/filings/0001193125-25-269542.md) | [203](/filings/0001193125-26-326123.md) | [191](/filings/0001193125-26-197277.md) | [204](/filings/0001193125-26-326123.md) |
| Shareholders' equity | $m | [1,382](/filings/0000950170-24-118989.md) | [1,447](/filings/0001193125-26-059371.md) | [1,485](/filings/0000950170-25-100901.md) | [1,527](/filings/0001193125-25-269542.md) | [1,587](/filings/0001193125-25-269542.md) | [1,617](/filings/0001193125-26-326123.md) | [1,659](/filings/0001193125-26-326123.md) | [1,715](/filings/0001193125-26-326123.md) | [1,745](/filings/0001193125-25-269542.md) | [1,761](/filings/0001193125-26-326123.md) | [1,704](/filings/0001193125-26-326123.md) | [1,684](/filings/0001193125-26-326123.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [60.3 d](/filings/0000950170-24-118989.md) | [37.1 d](/filings/0001193125-26-059371.md) | [72.2](/filings/0000950170-25-061835.md) | [67.0 d](/filings/0000950170-25-100901.md) | [79.9 d](/filings/0001193125-25-269542.md) | [34.7 d](/filings/0001193125-26-059371.md) | [30.6](/filings/0001193125-26-197277.md) | [51.9 d](/filings/0001193125-26-326123.md) | [97.2 d](/filings/0001193125-25-269542.md) | [31.1 d](/filings/0001193125-26-059371.md) | [109](/filings/0001193125-26-197277.md) | [25.0 d](/filings/0001193125-26-326123.md) |
| Capital expenditure | $m | [24.9 d](/filings/0000950170-24-118989.md) | [7.6 d](/filings/0001193125-26-059371.md) | [7.2](/filings/0000950170-25-061835.md) | [9.1 d](/filings/0000950170-25-100901.md) | [13.6 d](/filings/0001193125-25-269542.md) | [12.7 d](/filings/0001193125-26-059371.md) | [13.1](/filings/0001193125-26-197277.md) | [14.5 d](/filings/0001193125-26-326123.md) | [12.8 d](/filings/0001193125-25-269542.md) | [16.1 d](/filings/0001193125-26-059371.md) | [8.6](/filings/0001193125-26-197277.md) | [4.6 d](/filings/0001193125-26-326123.md) |
| Dividends paid | $m | [16.7](/filings/0000950170-23-058202.md) | [16.6 d](/filings/0000950170-24-018765.md) | [19.5](/filings/0000950170-24-052114.md) | [19.2](/filings/0000950170-24-089283.md) | [19.2](/filings/0000950170-24-118989.md) | [18.4 d](/filings/0000950170-25-024151.md) | [21.4](/filings/0000950170-25-061835.md) | [21.4](/filings/0000950170-25-100901.md) | [21.4](/filings/0001193125-25-269542.md) | [21.3 d](/filings/0001193125-26-059371.md) | [23.5](/filings/0001193125-26-197277.md) | [23.2](/filings/0001193125-26-326123.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-197277.md) | [0.0 d](/filings/0001193125-26-326123.md) | not reported | not reported | [67.1](/filings/0001193125-26-197277.md) | [48.1 d](/filings/0001193125-26-326123.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [47.5](/filings/0000950170-23-058202.md) | [47.6](/filings/0000950170-24-052114.md) | [47.6](/filings/0000950170-24-089283.md) | [47.6](/filings/0000950170-24-118989.md) | [47.6](/filings/0000950170-25-061835.md) | [47.6](/filings/0000950170-25-100901.md) | [47.7](/filings/0001193125-25-269542.md) | [47.7](/filings/0001193125-26-197277.md) | [47.7](/filings/0001193125-26-326123.md) | [47.7](/filings/0001193125-25-269542.md) | [47.2](/filings/0001193125-26-197277.md) | [46.7](/filings/0001193125-26-326123.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 45,966,835 at 2026-07-27, from the cover of the [10-Q filed 2026-07-30](/filings/0001193125-26-326123.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.